Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IBIO iBio	$0.79 +1.9%	$0.73	$0.56 ▼ $6.89	$15.26M	0.6	1.39 million shs	411,981 shs
NNVC NanoViricides	$1.44 +5.1%	$1.50	$0.94 ▼ $2.07	$23.14M	0.96	242,025 shs	109,767 shs
REXN Rexahn Pharmaceuticals		$2.06	$1.26 ▼ $4.26	$8.11M	0.98	162,968 shs	2,579 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IBIO iBio	+1.89%	+6.72%	+3.98%	-3.30%	-61.03%
NNVC NanoViricides	+5.11%	-4.00%	-17.71%	-19.55%	-28.89%
REXN Rexahn Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
IBIO iBio	1.8894 of 5 stars	3.5	0.0	0.0	0.0	2.5	0.0	0.6
NNVC NanoViricides	0.7424 of 5 stars	0.0	5.0	0.0	0.0	2.5	0.0	0.0
REXN Rexahn Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IBIO iBio	3.00	Buy	$5.00	532.11% Upside
NNVC NanoViricides	0.00	N/A	N/A	N/A
REXN Rexahn Pharmaceuticals	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest REXN, NNVC, and IBIO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
6/25/2025	IBIO iBio	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IBIO iBio	$375K	41.46	N/A	N/A	$1.41 per share	0.56
NNVC NanoViricides	N/A	N/A	N/A	N/A	$0.66 per share	N/A
REXN Rexahn Pharmaceuticals	N/A	N/A	N/A	N/A	$2.48 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IBIO iBio	-$24.91M	N/A	0.00	N/A	N/A	N/A	-73.15%	-45.51%	N/A
NNVC NanoViricides	-$8.29M	-$0.70	N/A	∞	N/A	N/A	-87.90%	-78.69%	N/A
REXN Rexahn Pharmaceuticals	-$8.64M	N/A	0.00	N/A	N/A	N/A	-72.60%	-55.68%	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
IBIO iBio	N/A	N/A	N/A	N/A	N/A
NNVC NanoViricides	N/A	N/A	N/A	N/A	N/A
REXN Rexahn Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IBIO iBio	0.05	1.76	1.76
NNVC NanoViricides	N/A	3.44	2.47
REXN Rexahn Pharmaceuticals	N/A	3.37	3.37

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IBIO iBio	7.90%
NNVC NanoViricides	10.30%
REXN Rexahn Pharmaceuticals	7.49%

Insider Ownership

Company	Insider Ownership
IBIO iBio	0.58%
NNVC NanoViricides	4.60%
REXN Rexahn Pharmaceuticals	1.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IBIO iBio	100	19.66 million	9.82 million	N/A
NNVC NanoViricides	20	16.07 million	14.92 million	Optionable
REXN Rexahn Pharmaceuticals	5	4.48 million	N/A	Optionable

REXN, NNVC, and IBIO Headlines

Recent News About These Companies

Rexahn Presents Updated Interim Data From Phase 2a Trial of RX-3117 in Advanced Bladder Cancer at the 2019 ASCO GU Symposium

August 16, 2024 | br.advfn.com

Aurinia Pharmaceuticals Inc AUPH

February 16, 2024 | morningstar.comM

MaxCyte Appoints Douglas Swirsky as Chief Financial Officer

March 27, 2023 | benzinga.com

Rexahn: Holes Galore in Serdaxin Data

January 1, 2023 | thestreet.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

REXN, NNVC, and IBIO Company Descriptions

iBio NYSE:IBIO

$0.79 +0.01 (+1.89%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$0.78 -0.01 (-1.01%)

As of 08/22/2025 07:50 PM Eastern

iBio, Inc., a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel. The company is also developing vaccine candidates, including IBIO-101, an antibody to reduce tumor growth; Endostatin E4 peptide for use in chemotherapy and immunotherapy; Trop-2 for the treatment Trop-2 positive cancers; MUC16, a tumor-associated epitope; anti-EGFRvIII antibody to treat glioblastoma and other cancers; CCR8 protein candidate for treatment of various cancers; PD-1 agonist for the treatment of rheumatoid arthritis and other inflammatory diseases; and IBIO-400 for the treatment of classical swine fever. iBio, Inc. has agreement with The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals; and a research collaboration with the National Institute of Allergy and Infectious Diseases to investigate the potential of the company's AI-driven epitope steering platform for the development of a vaccine for Lassa fever. The company was incorporated in 2008 and is headquartered in Bryan, Texas.

NanoViricides NYSE:NNVC

$1.44 +0.07 (+5.11%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$1.46 +0.02 (+1.67%)

As of 08/22/2025 07:55 PM Eastern

NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-CoV-2, nanoviricide drug which is in phase 1a/1b clinical trails for the treatment of Covid; and NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric cases. It also offers NV-CoV-2 Solution for injection, infusion, and inhalation to treat severe cases that are not yet hospitalized would be best performed by an injection; and injectable solution can be delivered directly into the lungs as a fog created using standard portable battery operated nebulizer devices which enables action at the most important site of infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia. In addition, the company provides Nanoviricide, a biomimetic platform technology designed to attack enveloped virus particles to deliver anti-viral payload into infected cells sparing uninfected cells to block replication cycle without toxicity. NanoViricides, Inc. was incorporated in 2005 and is headquartered in Shelton, Connecticut.

Rexahn Pharmaceuticals NASDAQ:REXN

Ocuphire Pharma, Inc. engages in the research and development of ophthalmic biopharmaceutical products. It focuses on developing and commercializing therapies for the treatment of several eye disorders. The company was founded by Mina Patel Soouch and Alan R. Meyer in February 2018 and is headquartered in Farmington Hills, MI.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time